Margetuximab: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 122: | Line 122: | ||
{{coststubd}} | {{coststubd}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 12:59, 18 March 2025
What Is Margetuximab?[edit]
- Margetuximab (Margenza) is a HER2/neu receptor antagonist.
What are the uses of this medicine?[edit]
- Margetuximab (Margenza) is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
How does this medicine work?[edit]
- Margetuximab-cmkb binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2).
- Upon binding to HER2-expressing tumor cells, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC).
Who Should Not Use this medicine ?[edit]
- This medicine have no usage limitations
Is this medicine FDA approved?[edit]
- It was approved for use in the United States in 2020.
How should this medicine be used?[edit]
- Administer Margenza as an intravenous infusion at 15 mg/kg over 120 minutes for the initial dose, then over a minimum of 30 minutes every 3 weeks for all subsequent doses.
- On days when both Margenza and chemotherapy are to be administered, Margenza may be administered immediately after chemotherapy completion.
What are the dosage forms and brand names of this medicine?[edit]
This medicine is available in fallowing doasage form: As injections: 250 mg/10 mL (25 mg/mL) in a single-dose vial
This medicine is available in fallowing brand namesː
- Margenza
What side effects can this medication cause?[edit]
Common possible side effects and laboratory abnormalities of this medicine include:
- fatigue/asthenia
- nausea
- diarrhea
- vomiting
- constipation
- headache
- pyrexia
- alopecia
- abdominal pain
- peripheral neuropathy
- arthralgia/myalgia
- cough
- decreased appetite
- dyspnea
- infusion-related reactions
- palmar-plantar erythrodysesthesia* extremity pain
What special precautions should I follow?[edit]
- Margenza may lead to reductions in left ventricular ejection fraction (LVEF).
- Evaluate cardiac function prior to and during treatment.
- Discontinue Margenza treatment for a confirmed clinically significant decrease in left ventricular function.
- Margenza can cause fetal harm when administered to a pregnant woman.
- Advise patients of the risk and need for effective contraception.
- If a significant infusion-associated reaction occurs, slow or interrupt the infusion and administer appropriate medical therapies.
What to do in case of emergency/overdose?[edit]
- In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.
- Overdose related information is also available online at poisonhelp.org/help.
- In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.
Can this medicine be used in pregnancy?[edit]
- Exposure to Margenza during pregnancy can cause embryo-fetal harm.
Can this medicine be used in children?[edit]
- Safety and effectiveness of Margenza have not been established in pediatric patients.
What should I know about storage and disposal of this medication?[edit]
- Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light until time of use.
- Do not freeze.
- Do not shake.
This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!
